NCT01897116View on ClinicalTrials.gov

A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

July 12, 2016

Study Completion Date

October 5, 2016

Conditions
Melanoma
Interventions
DRUG

Hydroxychloroquine (HCQ)

DRUG

Vemurafenib (VEM)

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT01897116 - A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma | Biotech Hunter | Biotech Hunter